Literature DB >> 10820333

Achievement of high cell density and high antibody productivity by a controlled-fed perfusion bioreactor process.

J D Yang1, Y Angelillo, M Chaudhry, C Goldenberg, D M Goldenberg.   

Abstract

Controlled feeding of nutrient supplements to a cell culture to enhance monoclonal antibody productivity has been practiced widely in high-yield, fed-batch processes. In this study, a similar feeding concept has been applied to a perfused culture and evaluated for the effects on bioreactor productivity and product quality. Our experimental results show that, by using such a "controlled-fed perfusion" approach, the volumetric antibody productivity (antibody per liter per day) was significantly increased by nearly twofold over the perfusion process, and surpassed fed-batch and batch processes by almost tenfold. The substantial boost in the overall productivity is attributable primarily to the combined effects of increased cell density as well as reduced product dilution. Both were achieved through careful nutrient supplementation in conjunction with metabolite minimization. As the manufacturing process evolved from roller bottles to the controlled-fed perfusion bioreactor system, the immunoreactivity and the cDNA sequences of the antibody were well preserved. However, the product glycosylation distribution patterns did alter. The controlled-feed perfusion process demonstrated a unique encompassment of the advantages of fed-batch and perfusion methods; that is, high product concentration with high volume throughput. Therefore, it may be very suitable for large-scale production of monoclonal antibodies. Copyright 2000 John Wiley & Sons, Inc.

Mesh:

Substances:

Year:  2000        PMID: 10820333

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  3 in total

1.  Long-term Continuous Production of Monoclonal Antibody by Hybridoma Cells Immobilized in a Fibrous-Bed Bioreactor.

Authors:  Hui Zhu; Shang-Tian Yang
Journal:  Cytotechnology       Date:  2004-01       Impact factor: 2.058

2.  Use of Taguchi's methods as a basis to optimize hybridoma cell line growth and antibody production in a spinner flask.

Authors:  Héla Kallel; Hind Zaïri; Samia Rourou; Makram Essafi; Ridha Barbouche; Koussay Dellagi; Dahmani M Fathallah
Journal:  Cytotechnology       Date:  2002-05       Impact factor: 2.058

3.  Bioprocess development for the production of mouse-human chimeric anti-epidermal growth factor receptor vIII antibody C12 by suspension culture of recombinant Chinese hamster ovary cells.

Authors:  Suwen Hu; Lei Deng; Huamao Wang; Yingping Zhuang; Ju Chu; Siliang Zhang; Zhonghai Li; Meijin Guo
Journal:  Cytotechnology       Date:  2011-02-05       Impact factor: 2.058

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.